Novavax Inc said on Thursday it could begin commercial manufacturing of a Covid-19 vaccine tailored for the Omicron coronavirus variant in January next year, while it tests whether or not its current vaccine works against the variant.
Novavax Inc said on Thursday it could begin commercial manufacturing of a Covid-19 vaccine tailored for the Omicron coronavirus variant in January next year, while it tests whether or not its current vaccine works against the variant.